Developments in the field of antidepressants, where do we go now?

European Neuropsychopharmacology

Volumn 25, Issue 5, 2015, Pages 657-670

  Artigas, Francesc ^a  

^a INST D INVESTIGACIONS B   (Spain)

Author keywords

5 hydroxytryptamine (serotonin) receptors; Antidepressant drugs; Glutamatergic neurotransmission; Major depression; Norepinephrine; Reuptake inhibition

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DEPTH STIMULATION; CINGULATE GYRUS; DESENSITIZATION; DRUG SYNTHESIS; DRUG TRANSPORT; ELECTROCONVULSIVE THERAPY; HEREDITY; HUMAN; HUMAN TISSUE; INNERVATION; MAJOR DEPRESSION; MIDBRAIN RAPHE NUCLEUS; MONOAMINERGIC SYSTEM; NERVE FIBER GROWTH; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC NERVE CELL; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROMOTER REGION; SEROTONIN RELEASE; SLEEP DEPRIVATION; SLEEP WAKING CYCLE; SYNAPTIC TRANSMISSION; ANIMAL; DEPRESSIVE DISORDER, MAJOR; GENETICS; PATHOPHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 84928272485     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.04.013     Document Type: Article

References (147)

1. Adell A., Casanovas J.M., Artigas F. Comparative study in the rat of the actions of different types of stress on the release of 5-HT in raphe nuclei and forebrain areas. Neuropharmacology 1997, 36:73-741.
2. Amargos-Bosch M., Bortolozzi A., Puig M.V., Serrats J., Adell A., Celada P., Toth M., Mengod G., Artigas F. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. Cereb. Cortex 2004, 14:281-299.
3. Andlin-Sobocki P., Jonsson B., Wittchen H.U., Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 2005, 12(1):1-27.
4. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol. Sci. 1993, 14:262.
5. Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol. Ther. 2013, 137:119-131.
6. Artigas F., Celada P., Laruelle M., Adell A. How does pindolol improve antidepressant action?. Trends Pharmacol. Sci. 2001, 22:224-228.
7. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 1994, 51:248-251.
8. Artigas F., Romero L., De Montigny C., Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996, 19:378-383.
9. Ballesteros J., Callado L.F. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J. Affect. Disord. 2004, 79:137-147.
10. Barbee J.G., Conrad E.J., Jamhour N.J. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J. Clin. Psychiatry 2004, 65:975-981.
11. Baune B.T., Hohoff C., Berger K., Neumann A., Mortensen S., Roehrs T., Deckert J., Arolt V., Domschke K. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008, 33:924-932.
12. Bejjani B.P., Damier P., Arnulf I., Thivard L., Bonnet A.M., Dormont D., Cornu P., Pidoux B., Samson Y., Agid Y. Transient acute depression induced by high-frequency deep-brain stimulation. N. Engl. J. Med. 1999, 340:1476-1480.
13. Bel N., Artigas F. Reduction of serotonergic function in rat brain by tryptophan depletion: effects in control and fluvoxamine-treated rats. J. Neurochem. 1996, 67:669-676.
14. Belozertseva I.V., Kos T., Popik P., Danysz W., Bespalov A.Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur. Neuropsychopharmacol. 2007, 17:172-179.
15. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007, 68:843-853.
16. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
17. Bhagwagar Z., Rabiner E.A., Sargent P.A., Grasby P.M., Cowen P.J. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol. Psychiatry 2004, 9:386-392.
18. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Putz B., Papiol S., Seaman S., Lucae S., Kohli M.A., Nickel T., Kunzel H.E., Fuchs B., Majer M., Pfennig A., Kern N., Brunner J., Modell S., Baghai T., Deiml T., Zill P., Bondy B., Rupprecht R., Messer T., Kohnlein O., Dabitz H., Bruckl T., Muller N., Pfister H., Lieb R., Mueller J.C., Lohmussaar E., Strom T.M., Bettecken T., Meitinger T., Uhr M., Rein T., Holsboer F., Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004, 36:1319-1325.
19. Blier P., De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994, 15:220-226.
20. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 1995, 15:217-222.
21. Blier P., Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol. Psychiatry 2003, 53:193-203.
22. Blomstedt P., Hariz M.I., Lees A., Silberstein P., Limousin P., Yelnik J., Agid Y. Acute severe depression induced by intraoperative stimulation of the substantia nigra: a case report. Parkinsonism Relat. Disord. 2008, 14:253-256.
23. Bonaventure P., Kelly L., Aluisio L., Shelton J., Lord B., Galici R., Miller K., Atack J., Lovenberg T.W., Dugovic C. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J. Pharmacol. Exp. Ther. 2007, 321:690-698.
24. Bortolozzi A., Castane A., Semakova J., Santana N., Alvarado G., Cortes R., Ferres-Coy A., Fernandez G., Carmona M.C., Toth M., Perales J.C., Montefeltro A., Artigas F. Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. Mol. Psychiatry 2012, 17:612-623.
25. Bradley S.R., Uslaner J.M., Flick R.B., Lee A., Groover K.M., Hutson P.H. The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling. Pharmacol. Biochem. Behav. 2012, 101:35-40.
26. Brown R.G., Pluck G. Negative symptoms: the 'pathology' of motivation and goal-directed behaviour. Trends Neurosci. 2000, 23:412-417.
27. Carvalho A.F., Machado J.R., Cavalcante J.L. Augmentation strategies for treatment-resistant depression. Curr. Opin. Psychiatry 2009, 22:7-12.
28. Celada P., Artigas F. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn Schmiedebergs Arch. Pharmacol. 1993, 347:583-590.
29. Celada P., Puig M.V., Casanovas J.M., Guillazo G., Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci. 2001, 21:9917-9929.
30. Chenu F., David D.J., Leroux-Nicollet I., Le Maitre E., Gardier A.M., Bourin M. Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system. J. Psychiatry Neurosci. 2008, 33:541-550.
31. Collier D.A., Stober G., Li T., Heils A., Catalano M., Di Bella D., Arranz M.J., Murray R.M., Vallada H.P., Bengel D., Muller C.R., Roberts G.W., Smeraldi E., Kirov G., Sham P., Lesch K.P. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol. Psychiatry 1996, 1:453-460.
32. Connolly, K.R., Thase, M.E., 2012. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs. 17, 105-126.
33. Conductier G., Dusticier N., Lucas G., Cote F., Debonnel G., Daszuta A., Dumuis A., Nieoullon A., Hen R., Bockaert J., Compan V. Adaptive changes in serotonin neurons of the raphe nuclei in 5-HT(4) receptor knock-out mouse. Eur. J. Neurosci. 2006, 24:1053-1062.
34. Cremers T.I., Giorgetti M., Bosker F.J., Hogg S., Arnt J., Mork A., Honig G., Bogeso K.P., Westerink B.H., den Boer H., Wikstrom H.V., Tecott L.H. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 2004, 29:1782-1789.
35. Cryan J.F., Lucki I. Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. J. Pharmacol. Exp. Ther. 2000, 295:1120-1126.
36. Danish University Antidepressant Group, 1986. Citalopram: Clinical Effect Profile in Comparison with Clomipramine. A Controlled Multicenter Study. Psychopharmacology (Berlin) 90, 131-138.
37. Danish University Antidepressant Group, 1990. Paroxetine: A Selective Serotonin Reuptake Inhibitor Showing Better Tolerance, but Weaker Antidepressant Effect than Clomipramine in a Controlled Multicenter Study. Journal of Affective Disorders, vol. 18, pp. 289-299.
38. de Foubert G., O'Neill M.J., Zetterstrom T.S. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression. Neuroscience 2007, 147:778-785.
39. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 1990, 47:411-418.
40. Depoortere R., Auclair A.L., Bardin L., Colpaert F.C., Vacher B., Newman-Tancredi A. F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur. Neuropsychopharmacol. 2010, 20:641-654.
41. Diaz S.L., Doly S., Narboux-Neme N., Fernandez S., Mazot P., Banas S.M., Boutourlinsky K., Moutkine I., Belmer A., Roumier A., Maroteaux L. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Mol. Psychiatry 2012, 17:154-163.
42. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., Huang Y., Gautier C., Mathis C. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 1999, 46:1375-1387.
43. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 2008, 213:93-118.
44. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
45. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
46. Dwyer J.M., Lepack A.E., Duman R.S. mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int. J. Neuropsychopharmacol. 2012, 15:429-434.
47. Eisensamer B., Rammes G., Gimpl G., Shapa M., Ferrari U., Hapfelmeier G., Bondy B., Parsons C., Gilling K., Zieglgansberger W., Holsboer F., Rupprecht R. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol. Psychiatry 2003, 8:994-1007.
48. Fan P. Facilitation of 5-hydroxytryptamine3 receptor desensitization by fluoxetine. Neuroscience 1994, 62:515-522.
49. Ferres-Coy A., Santana N., Castane A., Cortes R., Carmona M.C., Toth M., Montefeltro A., Artigas F., Bortolozzi A. Acute 5-HT(1)A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions. Psychopharmacology (Berlin) 2013, 225:61-74.
50. Gabbott P.L., Warner T.A., Jays P.R., Salway P., Busby S.J. Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic centers. J. Comp. Neurol. 2005, 492:145-177.
51. Gobert A., Rivet J.M., Cistarelli L., Millan M.J. Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J. Neurochem. 1997, 68:1159-1163.
52. Groenewegen H.J., Uylings H.B. The prefrontal cortex and the integration of sensory, limbic and autonomic information. Prog. Brain Res. 2000, 126:3-28.
53. Gurevich I., Tamir H., Arango V., Dwork A.J., Mann J.J., Schmauss C. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002, 34:349-356.
54. Gustavsson A., Svensson M., Jacobi F., Allgulander C., Alonso J., Beghi E., Dodel R., Ekman M., Faravelli C., Fratiglioni L., Gannon B., Jones D.H., Jennum P., Jordanova A., Jonsson L., Karampampa K., Knapp M., Kobelt G., Kurth T., Lieb R., Linde M., Ljungcrantz C., Maercker A., Melin B., Moscarelli M., Musayev A., Norwood F., Preisig M., Pugliatti M., Rehm J., Salvador-Carulla L., Schlehofer B., Simon R., Steinhausen H.C., Stovner L.J., Vallat J.M., den Bergh P.V., van Os J., Vos P., Xu W., Wittchen H.U., Jonsson B., Olesen J. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011, 21:718-779.
55. Haddjeri N., Blier P., De Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 1998, 18:10150-10156.
56. Hajos M., Richards C.D., Szekely A.D., Sharp T. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience 1998, 87:95-108.
57. Hamani C., Diwan M., Macedo C.E., Brandao M.L., Shumake J., Gonzalez-Lima F., Raymond R., Lozano A.M., Fletcher P.J., Nobrega J.N. Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol. Psychiatry 2010, 67:117-124.
58. Harro J., Oreland L. Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Res. Brain Res. Rev. 2001, 38:79-128.
59. Hedlund P.B. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berlin) 2009, 206:345-354.
60. Hedlund P.B., Sutcliffe J.G. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 2004, 25:481-486.
61. Hervas I., Queiroz C.M., Adell A., Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br. J. Pharmacol. 2000, 130:160-166.
62. Holmes A., Heilig M., Rupniak N.M., Steckler T., Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci. 2003, 24:580-588.
63. Holtzheimer P.E., Kelley M.E., Gross R.E., Filkowski M.M., Garlow S.J., Barrocas A., Wint D., Craighead M.C., Kozarsky J., Chismar R., Moreines J.L., Mewes K., Posse P.R., Gutman D.A., Mayberg H.S. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch. Gen. Psychiatry 2012, 69:150-158.
64. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
65. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., Roth B.L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312.
66. Jodo E., Chiang C., Aston-Jones G. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience 1998, 83:63-79.
67. Kellner C.H., Knapp R.G., Petrides G., Rummans T.A., Husain M.M., Rasmussen K., Mueller M., Bernstein H.J., O'Connor K., Smith G., Biggs M., Bailine S.H., Malur C., Yim E., McClintock S., Sampson S., Fink M. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch. Gen. Psychiatry 2006, 63:1337-1344.
68. Kennedy S.H., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 2006, 16:93-100.
69. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62:593-602.
70. Kinon B.J., Zhang L., Millen B.A., Osuntokun O.O., Williams J.E., Kollack-Walker S., Jackson K., Kryzhanovskaya L., Jarkova N. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol. 2011, 31:349-355.
71. Kobayashi K., Ikeda Y., Haneda E., Suzuki H. Chronic fluoxetine bidirectionally modulates potentiating effects of serotonin on the hippocampal mossy fibre synaptic transmission. J. Neurosci. 2008, 28:6272-6280.
72. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
73. Learned S., Graff O., Roychowdhury S., Moate R., Krishnan K.R., Archer G., Modell J.G., Alexander R., Zamuner S., Lavergne A., Evoniuk G., Ratti E. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J. Psychopharmacol. 2012, 26:653-662.
74. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., Sequeira A., Kushwaha N., Morris S.J., Basak A., Ou X.M., Albert P.R. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J. Neurosci. 2003, 23:8788-8799.
75. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
76. Licinio J., Dong C., Wong M.L. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry 2009, 66:488-497.
77. Llado-Pelfort L., Assie M.B., Newman-Tancredi A., Artigas F., Celada P. Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. Br. J. Pharmacol. 2010, 160:1929-1940.
78. Lozano A.M., Lipsman N. Probing and regulating dysfunctional circuits using deep brain stimulation. Neuron 2013, 77:406-424.
79. Lucas G., Compan V., Charnay Y., Neve R.L., Nestler E.J., Bockaert J., Barrot M., Debonnel G. Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biol. Psychiatry 2005, 57:918-925.
80. Lucas G., Rymar V.V., Du J., Mnie-Filali O., Bisgaard C., Manta S., Lambas-Senas L., Wiborg O., Haddjeri N., Pineyro G., Sadikot A.F., Debonnel G. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 2007, 55:712-725.
81. Marek G.J., Carpenter L.L., McDougle C.J., Price L.H. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 2003, 28:402-412.
82. Martinez D., Hwang D., Mawlawi O., Slifstein M., Kent J., Simpson N., Parsey R.V., Hashimoto T., Huang Y., Shinn A., Van Heertum R., Abi-Dargham A., Caltabiano S., Malizia A., Cowley H., Mann J.J., Laruelle M. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 2001, 24:209-229.
83. Martin-Ruiz R., Puig M.V., Celada P., Shapiro D.A., Roth B.L., Mengod G., Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J. Neurosci. 2001, 21:9856-9866.
84. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., Schwalb J.M., Kennedy S.H. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
85. Mitsukawa K., Yamamoto R., Ofner S., Nozulak J., Pescott O., Lukic S., Stoehr N., Mombereau C., Kuhn R., McAllister K.H., van der P.H., Cryan J.F., Flor P.J. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:18712-18717.
86. Monsma F.J., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 1993, 43:320-327.
87. Morales M., Bloom F.E. The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J. Neurosci. 1997, 17:3157-3167.
88. Mork A., Pehrson A., Brennum L.T., Nielsen S.M., Zhong H., Lassen A.B., Miller S., Westrich L., Boyle N.J., Sanchez C., Fischer C.W., Liebenberg N., Wegener G., Bundgaard C., Hogg S., Bang-Andersen B., Stensbol T.B. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J. Pharmacol. Exp. Ther. 2012, 340:666-675.
89. Moses-Kolko E.L., Price J.C., Thase M.E., Meltzer C.C., Kupfer D.J., Mathis C.A., Bogers W.D., Berman S.R., Houck P.R., Schneider T.N., Drevets W.C. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse 2007, 61:523-530.
90. Mullins U.L., Gianutsos G., Eison A.S. Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology 1999, 21:352-367.
91. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
92. Murray C.J., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
93. Neff C.D., Abkevich V., Packer J.C., Chen Y., Potter J., Riley R., Davenport C., DeGrado W.J., Jammulapati S., Bhathena A., Choi W.S., Kroeger P.E., Metzger R.E., Gutin A., Skolnick M.H., Shattuck D., Katz D.A. Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression. Mol. Psychiatry 2009, 14:621-630.
94. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
95. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 2006, 59:1151-1159.
96. Neumaier J.F., Root D.C., Hamblin M.W. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology 1996, 15:515-522.
97. Nord M., Finnema S.J., Halldin C., Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int. J. Neuropsychopharmacol. 2013, 1-10. (Epub ahead of print).
98. O'Connor R.M., Finger B.C., Flor P.J., Cryan J.F. Metabotropic glutamate receptor 7: at the interface of cognition and emotion. Eur. J. Pharmacol. 2010, 639:123-131.
99. Page M.E., Cryan J.F., Sullivan A., Dalvi A., Saucy B., Manning D.R., Lucki I. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J. Pharmacol. Exp. Ther. 2002, 302:1220-1227.
100. Parsey R.V., Ogden R.T., Miller J.M., Tin A., Hesselgrave N., Goldstein E., Mikhno A., Milak M., Zanderigo F., Sullivan G.M., Oquendo M.A., Mann J.J. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol. Psychiatry 2010, 68:170-178.
101. Parsey R.V., Oquendo M.A., Ogden R.T., Olvet D.M., Simpson N., Huang Y.Y., Van Heertum R.L., Arango V., Mann J.J. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol. Psychiatry 2006, 59:106-113.
102. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
103. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997, 349:1594-1597.
104. Perez V., Soler J., Puigdemont D., Alvarez E., Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch. Gen. Psychiatry 1999, 56:375-379.
105. Perlis R.H., Moorjani P., Fagerness J., Purcell S., Trivedi M.H., Fava M., Rush A.J., Smoller J.W. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology 2008, 33:2810-2819.
106. Peters E.J., Slager S.L., McGrath P.J., Knowles J.A., Hamilton S.P. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry 2004, 9:879-889.
107. Portella M.J., Diego-Adelino J., Puigdemont D., Perez-Egea R., Alvarez E., Artigas F., Perez V. Pindolol augmentation enhances response outcomes in first depressive episodes. Eur. Neuropsychopharmacol. 2009, 19:516-519.
108. Portella M.J., Diego-Adelino J., Ballesteros J., Puigdemont D., Oller S., Santos B., Alvarez E., Artigas F., Perez V. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J. Clin. Psychiatry 2011, 72:962-969.
109. Price J.L., Drevets W.C. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn. Sci. 2012, 16:61-71.
110. Puig M.V., Santana N., Celada P., Mengod G., Artigas F. In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb. Cortex 2004, 14:1365-1375.
111. Puig, M.V., Artigas, F., Celada, P. 2005. Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: Involvement of serotonin and GABA. Cereb Cortex 15, 1-14.
112. Puigdemont D., Perez-Egea R., Portella M.J., Molet J., Diego-Adelino J., Gironell A., Radua J., Gomez-Anson B., Rodriguez R., Serra M., de Quintana C., Artigas F., Alvarez E., Perez V. Deep brain stimulation of the subcallosal cingulate gyrus: further evidence in treatment-resistant major depression. Int. J. Neuropsychopharmacol. 2011, 1-13.
113. Romero L., Bel N., Artigas F., De Montigny C., Blier P. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 1996, 15:349-360.
114. Romero L., Celada P., Martin-Ruiz R., Diaz-Mataix L., Mourelle M., Delgadillo J., Hervas I., Artigas F. Modulation of serotonergic function in rat brain by VN2222, a serotonin reuptake inhibitor and 5-HT1A receptor agonist. Neuropsychopharmacology 2003, 28:445-456.
115. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163:1905-1917.
116. Sara S.J., Herve-Minvielle A. Inhibitory influence of frontal cortex on locus coeruleus neurons. Proc. Natl. Acad. Sci. USA 1995, 92:6032-6036.
117. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat. Neurosci. 2007, 10:1110-1115.
118. Sargent P.A., Kjaer K.H., Bench C.J., Rabiner E.A., Messa C., Meyer J., Gunn R.N., Grasby P.M., Cowen P.J. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 2000, 57:174-180.
119. Scorza M.C., Llado-Pelfort L., Oller S., Cortes R., Puigdemont D., Portella M.J., Perez-Egea R., Alvarez E., Celada P., Perez V., Artigas F. Preclinical and clinical characterisation of the selective serotonin-1A receptor antagonist DU-125530 for antidepressant treatment. Br. J. Pharmacol. 2011, 167:1021-1034.
120. Seminowicz D.A., Mayberg H.S., McIntosh A.R., Goldapple K., Kennedy S., Segal Z., Rafi-Tari S. Limbic-frontal circuitry in major depression: a path modeling metanalysis. NeuroImage 2004, 22:409-418.
121. Serrats J., Artigas F., Mengod G., Cortes R. An autoradiographic study of the influence of pindolol upon [35S]GTPgammaS binding in rat, guinea pig and human brain. Int. J. Neuropsychopharmacol. 2004, 7:27-34.
122. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 2007, 12:247-257.
123. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., Buras W.R., Bymaster F.P., Zhang W., Spencer K.A., Feldman P.D., Meltzer H.Y. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 2001, 158:131-134.
124. Skolnick P., Basile A.S. Triple reuptake inhibitors ("broad spectrum" antidepressants). CNS Neurol. Disord. Drug Targets 2007, 6:141-149.
125. Slawinska A., Wieronska J.M., Stachowicz K., Palucha-Poniewiera A., Uberti M.A., Bacolod M.A., Doller D., Pilc A. Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu(4) receptor. Neuropharmacology 2012, 65:225-235.
126. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 1998, 3:508-511.
127. Stahl S.M. The serotonin-7 receptor as a novel therapeutic target. J. Clin. Psychiatry 2010, 71:1414-1415.
128. Stockmeier C.A., Shapiro L.A., Dilley G.E., Kolli T.N., Friedman L., Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J. Neurosci. 1998, 18:7394-7401.
129. Tatarczynska E., Klodzinska A., Stachowicz K., Chojnacka-Wojcik E. Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Behav. Pharmacol. 2004, 15:523-534.
130. Thakker, D.R., Natt, F., Hüsken, D., van der Putten, H., Maier, R., Hoyer, D., Cryan, J.F., 2005. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatry 10, 782-789.
131. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001, 178:234-241.
132. Thase M.E., Trivedi M.H., Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995, 12:185-219.
133. Thierry A.M., Chevalier G., Ferron A., Glowinski J. Diencephalic and mesencephalic efferents of the medial prefrontal cortex in the rat: electrophysiological evidence for the existence of branched axons. Exp. Brain Res. 1983, 50:275-282.
134. Tollefson G.D., Holman S.L. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int. Clin. Psychopharmacol. 1994, 9:245-250.
135. Tong Z.Y., Overton P.G., Clark D. Stimulation of the prefrontal cortex in the rat induces patterns of activity in midbrain dopaminergic neurons which resemble natural burst events. Synapse 1996, 22:195-208.
136. Tran P., Skolnick P., Czobor P., Huang N.Y., Bradshaw M., McKinney A., Fava M. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J. Psychiatr. Res. 2012, 46:64-71.
137. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
138. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., Dose T., Ebinger M., Rosenhagen M., Kohli M., Kloiber S., Salyakina D., Bettecken T., Specht M., Putz B., Binder E.B., Muller-Myhsok B., Holsboer F. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008, 57:203-209.
139. Wesolowska A., Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 2007, 52:1274-1283.
140. Wesolowska A., Nikiforuk A., Stachowicz K., Tatarczynska E. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 2006, 51:578-586.
141. Wesolowska A., Tatarczynska E., Nikiforuk A., Chojnacka-Wojcik E. Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur. J. Pharmacol. 2007, 555:43-47.
142. Whale R., Terao T., Cowen P., Freemantle N., Geddes J. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. J. Psychopharmacol. 2010, 24:513-520.
143. Wong M.L., Dong C., Maestre-Mesa J., Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol. Psychiatry 2008, 13:800-812.
144. Wong M.L., Whelan F., Deloukas P., Whittaker P., Delgado M., Cantor R.M., McCann S.M., Licinio J. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc. Natl. Acad. Sci. USA 2006, 103:15124-15129.
145. Yoshida K., Takahashi H., Higuchi H., Kamata M., Ito K., Sato K., Naito S., Shimizu T., Itoh K., Inoue K., Suzuki T., Nemeroff C.B. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatry 2004, 161:1575-1580.
146. Zanardi R., Benedetti F., Di Bella D., Catalano M., Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol. 2000, 20:105-107.
147. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.